echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Tumor-soaked lymphocyte density is positively related to the prognostic prognosticity of NSCLC patients with immunotherapy!

    Eur J Cancer: Tumor-soaked lymphocyte density is positively related to the prognostic prognosticity of NSCLC patients with immunotherapy!

    • Last Update: 2021-02-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Immuno checkpoint inhibitors (ICI) are one of the most important milestones in cancer treatment.
    for non-small cell lung cancer (NSCLC), ICI single-drug or combination with chemotherapy or other ICI can improve patient survival compared to chemotherapy alone, and is now the standard treatment for NSCLC.
    the morphological evaluation of tumor-immersive lymphocytes (TIL) and the prognostic prognosticity of ICI or chemotherapy in patients with advanced NSCLC were not clear.
    study is a multi-center retrospective study designed to analyze the correlation between TIL and the prognosticity of ICI or chemotherapy in patients with advanced NSCLC.
    the study included two queues: 221 patients treated with navuda resistance between November 2012 and February 2017;
    patients with tissues that can be used for intersted TIL evaluation.
    high TIL count (high TIL) is defined as ≥ 10% density.
    end point is total lifetime (OS).
    64% were male, the middle age was 63, 82.3% were smokers, 77% had a performance status of ≤1 points, and 63% were adenocarcinoma.
    high TIL rate of 22%, associated with OS and progress-free survival rate (PFS) (risk ratio of 0.48, 95% CI 0.28-0.81; 0.40, 95%CI 0.25-0.64)。
    PFS in the high TIL group and the low TIL group were 13.0 months (95% CI 5.0-not reached) and 2.2 months (1.7-3.0), respectively, while the medium OS was not reached (12.2-not reached) and 8.4 months (5.0-11.6), respectively.
    high TIL is associated with total efficiency (ORR) and disease control rate (DCR) (P.lt;0.0001).
    in the chemotherapy queue, 69 percent were male, 89 percent were smokers, 86 percent were in ≤1 and 90 percent were adenocarcinoma.
    high TIL is 37%.
    PFS and OS were 5.7 months (95% CI 4.9-6.7) and 11.7 months (9.3-13.0), respectively, independent of TIL.
    summary, in the real immunotherapy queue of NSCLC patients, high TIL was associated with a good prognosis, but independent of the prognosis of patients with chemotherapy, suggesting that TIL could be used to screen patients suitable for immunotherapy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.